Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

intervet international b.v. - actinobacillus pleuropneumoniae toxoid type 1, apxi, (105 kd), actinobacillus pleuropneumoniae toxoid type 2, apxii, (105 kd), actinobacillus pleuropneumoniae toxoid type 3, apxiii, (120 kd), actinobacillus pleuropneumoniae ydre membranprotein toxoid - injektionsvæske, suspension - svin

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

pharmaménta aps - actinobacillus pleuropneumoniae toxoid type 1, apxi, (105 kd), actinobacillus pleuropneumoniae toxoid type 2, apxii, (105 kd), actinobacillus pleuropneumoniae toxoid type 3, apxiii, (120 kd), actinobacillus pleuropneumoniae ydre membranprotein toxoid - injektionsvæske, suspension

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

chemvet dk a/s - actinobacillus pleuropneumoniae toxoid type 2, apxii, (105 kd), actinobacillus pleuropneumoniae toxoid type 3, apxiii, (120 kd), actinobacillus pleuropneumoniae, serotype 2, stamme app2tr98, inaktiveret - injektionsvæske, emulsion

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

salfarm danmark a/s - actinobacillus pleuropneumoniae toxoid apx ii, stamme wslb 3012, actinobacillus pleuropneumoniae toxoid apx iii, stamme wslb 3012, actinobacillus pleuropneumoniae, serovar 2, stamme wslb 3012 - injektionsvæske, emulsion - svin

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

chemvet dk a/s - actinobacillus pleuropneumoniae (inakt.), actinobacillus pleuropneumoniae serotype 9, stamme app9kl97, inaktiveret, actinobacillus pleuropneumoniae toxoid type 1, apxi, (105 kd), actinobacillus pleuropneumoniae toxoid type 2, apxii, (105 kd), actinobacillus pleuropneumoniae toxoid type 3, apxiii, (120 kd), actinobacillus pleuropneumoniae, serotype 2, stamme app2tr98, inaktiveret - injektionsvæske, emulsion - svin

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

salfarm danmark a/s - actinobacillus pleuropneumoniae serotype 5 strain wslb 3079, actinobacillus pleuropneumoniae serotype 6 strain wslb 3075, actinobacillus pleuropneumoniae toxoid type 1, apxi, (105 kd), actinobacillus pleuropneumoniae toxoid type 2, apxii, (105 kd), actinobacillus pleuropneumoniae toxoid type 3, apxiii, (120 kd), actinobacillus pleuropneumoniae, serovar 2, stamme wslb 3012 - injektionsvæske, emulsion - svin

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

salfarm danmark a/s - actinobacillus pleuropneumoniae apx ii toxoid, stamme wslb 3075, actinobacillus pleuropneumoniae apx iii toxoid, stamme wslb 3075, actinobacillus pleuropneumoniae serotype 6 strain wslb 3075 - injektionsvæske, emulsion - svin

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

axellus a/s - lactobacillus gasseri, lactobacillus rhamnosus - vaginalkapsler, hårde

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

exeltis healthcare s.l - estriol, lactobacillus acidophilus - vaginaltabletter - 0,03 mg/50 mg

Den Europæiske Union - dansk - EMA (European Medicines Agency)

ceva santé animale - tulathromycin - antibakterielle midler til systemisk brug - cattle; pigs; sheep - cattle: treatment and metaphylaxis of bovine respiratory disease (brd) associated with mannheimia haemolytica, pasteurella multocida, histophilus somni and mycoplasma bovis susceptible to tulathromycin. tilstedeværelsen af ​​sygdommen i besætningen bør etableres inden metafylaktisk behandling. treatment of infectious bovine keratoconjunctivitis (ibk) associated with moraxella bovis susceptible to tulathromycin. pigs: treatment and metaphylaxis of swine respiratory disease (srd) associated with actinobacillus pleuropneumoniae, pasteurella multocida, mycoplasma hyopneumoniae, haemophilus parasuis and bordetella bronchiseptica susceptible to tulathromycin. tilstedeværelsen af ​​sygdommen i besætningen bør etableres inden metafylaktisk behandling. the product should only be used if pigs are expected to develop the disease within 2–3 days. får: behandling af de tidlige stadier af infektiøs pododermatitis (fodrot) forbundet med virulent dichelobacter nodosus, der kræver systemisk behandling.